Development and multi-center clinical trials of an up-converting phosphor technology-based point-of-care (UPT-POCT) assay for rapid COVID-19 diagnosis and prediction of protective effects

Table 3 The correlation between RP rates, accumulated RP rates, protection rates, and T/C ratios

RP rate for each titer					Accumulated RP (ARP) rate					Protection rate		T/C ratio
Neutralizing Titer	NRP cases	RP cases	Sum	RP rate ^a	Neutralizing Titer	Accumulated NRP cases	Accumulated RP cases	Sum	ARP rate ^b	Total –Accumulated RP	Protection rate^c	MEAN	SD
1:4	9	6	15	40%	≥1:4	213	99	312	32%	213	68%	0.738	0.509
1:8	20	12	32	38%	≥1:8	204	93	297	31%	219	70%	1.246	0.914
1:16	32	12	44	27%	≥1:16	184	81	265	31%	231	74%	1.960	1.143
1:32	42	35	77	45%	≥1:32	152	69	221	31%	243	78%	3.287	2.102
1:64	31	10	41	24%	≥1:64	110	34	144	24%	278	89%	4.380	2.677
1:128	41	16	57	28%	≥1:128	79	24	103	23%	288	92%	5.546	3.033
1:256	22	5	27	19%	≥1:256	38	8	46	17%	304	97%	6.204	3.71
1:512	8	3	11	27%	≥1:512	16	3	19	16%	309	99%	6.339	1.414
1:1024	8	0	8	0	≥1:1024	8	0	8	0%	312	100%	9.689	5.73
Total	213	99	312

^{a, b} RP and ARP rates is calculated as the ratio of the number of RP cases (or accumulated cases) to the sum of RP and NRP patients (or accumulated cases) at each specific titer
^c Protection rate against RP = (312- accumulated RP cases)/312

ISSN: 1471-2180